Lazard has announced that Dr. Geoffrey Porges has joined the firm as a Managing Director within its Healthcare Advisory Group, where he will advise on transactions across the diversified biopharmaceutical sector. This appointment brings a seasoned leader with more than three decades of experience in advisory, executive, and investment roles to the firm, further strengthening Lazard’s expertise in healthcare.
Dr. Porges most recently served as Executive Vice President and Chief Financial Officer at Schrödinger, where he oversaw a wide range of responsibilities, including financial operations, investor relations, corporate communications, strategic planning, and business development. Before that, he was a highly regarded equity research analyst, serving as head of biopharma equity research at SVB Leerink and as a senior biotechnology equity research analyst at Sanford C. Bernstein. During his time on Wall Street, he was consistently recognized as one of the top analysts in the biotechnology sector.
Earlier in his career, Dr. Porges held senior roles at BTG PLC and Merck & Co., where he gained valuable experience in both operational and strategic aspects of the biopharmaceutical industry. His background encompasses corporate leadership, financial strategy, and in-depth sector analysis, positioning him well to guide complex transactions and navigate industry trends.
Dr. Porges holds a medical degree from the University of Sydney and an MBA from Harvard Business School, where he graduated as a Baker Scholar, an honor awarded to the top students in the program. His unique combination of medical training, financial expertise, and industry leadership gives him a comprehensive perspective on the challenges and opportunities facing biopharmaceutical companies today.
By bringing Dr. Porges into its Healthcare Advisory Group, Lazard is reinforcing its commitment to providing clients with world-class expertise in one of the most dynamic and strategically important sectors of the global economy. His appointment reflects the firm’s focus on advising clients through the complexities of healthcare innovation, investment, and growth.
KEY QUOTES:
“We are thrilled to welcome Geoffrey to Lazard. His deep understanding of the biopharmaceutical industry’s strategic and financial landscape, coupled with his ability to help companies translate scientific innovation into actionable business strategies, will empower our clients to strengthen their competitive positions, capitalize on growth opportunities, and build resilient companies in a challenging geopolitical and macroeconomic environment.”
David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare
“Lazard’s deep expertise in healthcare and biopharma makes it an ideal platform to help clients tackle key strategic and financial challenges. I’m excited to join this world-class team and begin working with clients as they make critical decisions in a dynamic environment.”
Dr. Porges
